News
Pharma Update | Fingolimod Preliminary Injunction also rejected in Appeal
In its interim relief decision of 18 October 2022, the Court of Appeal of The Hague affirms the first instance decision in which the PI judge of the District Court rejected Novartis’ claim for a preliminary injunction against Mylan. The Court of Appeal also held Novartis’ EP 2 959 894 (“EP 894”) re fingolimod 0,5
Read more ›
Pharma update | PI judge holds fingolimod 0.5 mg patent provisionally invalid
In its interim relief decision of 21 June 2022 the PI Judge of the District Court of The Hague held Novartis’ EP 2 959 894 (“EP 894”) re fingolimod 0.5 mg provisionally invalid. This is the first substantive PI decision on this matter in Europa, where several proceedings between Novartis and Mylan are pending. In
Read more ›
Pharma update | Apixaban patent and SPC provisionally held invalid
In its decision of 10 May 2022 in PI proceedings between Bristol-Myers Squibb Holdings Ireland Unlimited Company (“BMS”) and Sandoz B.V. (“Sandoz”), the PI judge of the District Court of The Hague denied BMS’ claim for injunctive relief regarding the sale of generic apixaban by Sandoz. According to the Judge, there is no inventive step
Read more ›
Legal 500 EMEA 2022: “Partner involvement, all areas in-house, professional juniors”
This week the Legal 500 published its’ 2022 edition. We are honoured to again have received excellent rankings this year. BarentsKrans has been ranked as Top Tier Firm in Employment Law and has been recommended in no less than ten practice areas. A special mention goes to Joost Fanoy who was listed as Leading Individual
Read more ›
Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed
In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Read more ›
Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent
In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›
Pharma update | Cross-border preliminary injunction granted regarding deferasirox
At the request of Novartis the Provisions Judge of the District Court of The Hague granted a preliminary injunction against Mylan BV for the alleged imminent infringement of Novartis’ paediatric extension (‘PE’) of Dutch SPC 300248 (‘SPC ‘248’) based on EP 0 914 118 (‘EP ‘118’).The product at issue contains deferasirox as the active ingredient
Read more ›
IAM Patent 1000 2020: BarentsKrans’ star is rising
IAM has just published the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals – a guide that identifies the top patent professionals in key jurisdictions around the globe. We are proud to report that recommendations from clients and peers have resulted in BarentsKrans’ IP & Technology team ascending to the silver category
Read more ›
Pharma Update | Tadalafil dose patent invalid: Court of Appeal confirms judgment 1st instance
The Court of Appeal of The Hague has confirmed the judgment in first instance, in which ICOS’ patent EP 1 173 181 B3 (‘EP ‘181’), claiming a 1-5 mg dosage range for tadalafil, was invalidated. EP ‘181 relates to tadalafil for the treatment of erectile dysfunction in a specific (low) dosage range. This finding was
Read more ›
Pharma update: pemetrexed tromethamine does not infringe pemetrexed disodium patent
In its judgment of 19 June 2019, the District Court of The Hague ruled that Fresenius Kabi’s pemetrexed tromethamine falls outside the scope of protection of Eli Lilly’s patent for pemetrexed disodium. This final relief decision deviates from earlier decisions in interim relief proceedings and decisions by several foreign courts. Eli Lilly (“Lilly”) markets the
Read more ›
